Agonist-like SERM effects on ERα-mediated repression of MMP1 promoter activity predict in vivo effects on bone and uterus

WHI Writing Group, Writing Group for the Women's Health Initiative Investigators, Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial, JAMA 288 (2002) 321–333. Smith, 1994, Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man, N. Engl. J. Med., 331, 1056, 10.1056/NEJM199410203311604 Korach, 2000, Estrogen receptor knock-out mice: molecular and endocrine phenotypes, J. Soc. Gynecol. Investig., 7, S16, 10.1016/S1071-5576(99)00057-X Jilka, 1998, Cytokines, bone remodeling, and estrogen deficiency: a 1998 update, Bone, 23, 75, 10.1016/S8756-3282(98)00077-5 Kassem, 1996, Estrogen inhibits interleukin-6 production and gene expression in a human osteoblastic cell line with high levels of estrogen receptors, J. Bone Miner. Res., 11, 193, 10.1002/jbmr.5650110208 Pacifici, 1996, Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis, J. Bone Miner. Res., 11, 1043, 10.1002/jbmr.5650110802 Cenci, 2000, Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha, J. Clin. Invest., 106, 1229, 10.1172/JCI11066 Khosla, 2002, Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men, J. Clin. Endocrinol. Metab., 87, 1550, 10.1210/jc.87.4.1550 Shevde, 2000, Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression, Proc. Natl. Acad. Sci. U.S.A., 97, 7829, 10.1073/pnas.130200197 Srivastava, 2001, Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation, J. Biol. Chem., 276, 8836, 10.1074/jbc.M010764200 Chang, 1996, The effect of tamoxifen and hormone replacement therapy on serum cholesterol, bone mineral density and coagulation factors in healthy postmenopausal women participating in a randomized, controlled tamoxifen prevention study, Ann. Oncol., 7, 671, 10.1093/oxfordjournals.annonc.a010715 Powles, 1996, Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women, J. Clin. Oncol., 14, 78, 10.1200/JCO.1996.14.1.78 Barrett-Connor, 2004, Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes Of Raloxifene Evaluation (MORE) randomized trial, J. Bone Miner. Res., 19, 1270, 10.1359/JBMR.040406 Barrett-Connor, 2002, Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes Of Raloxifene Evaluation) randomized trial, JAMA, 287, 847, 10.1001/jama.287.7.847 Martino, 2004, The role of selective estrogen receptor modulators in the prevention of breast cancer: comparison of the clinical trials, Oncologist, 9, 116, 10.1634/theoncologist.9-2-116 Delmas, 2002, Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial, J. Clin. Endocrinol. Metab., 87, 3609, 10.1210/jc.87.8.3609 Scott, 1999, Raloxifene: a selective estrogen receptor modulator, Am. Fam. Physician, 60, 1131 Sibonga, 1998, Effect of the high-affinity estrogen receptor ligand ICI 182,780 on the rat tibia, Endocrinology, 139, 3736, 10.1210/en.139.9.3736 Shang, 2002, Molecular determinants for the tissue specificity of SERMs, Science, 295, 2465, 10.1126/science.1068537 Stein, 1995, Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta, Mol. Cell Biol., 15, 4971, 10.1128/MCB.15.9.4971 Jakacka, 2001, Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway, J. Biol. Chem., 276, 13615, 10.1074/jbc.M008384200 Paech, 1997, Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites, Science, 277, 1508, 10.1126/science.277.5331.1508 Webb, 1995, Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens, Mol. Endocrinol., 9, 443, 10.1210/me.9.4.443 Yang, 1996, Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene, Science, 273, 1222, 10.1126/science.273.5279.1222 Montano, 1996, Human estrogen receptor ligand activity inversion mutants: receptors that interpret antiestrogens as estrogens and estrogens as antiestrogens and discriminate among different antiestrogens, Mol. Endocrinol., 10, 230, 10.1210/me.10.3.230 Montano, 1998, Transcriptional regulation of the human quinone reductase gene by antiestrogen-liganded estrogen receptor-alpha and estrogen receptor-beta, J. Biol. Chem., 273, 25443, 10.1074/jbc.273.39.25443 Green, 1986, A superfamily of potentially oncogenic hormone receptors, Nature, 324, 615, 10.1038/324615a0 Greene, 1986, Sequence and expression of human estrogen receptor complementary DNA, Science, 231, 1150, 10.1126/science.3753802 Walter, 1985, Cloning of the human estrogen receptor cDNA, Proc. Natl. Acad. Sci. U.S.A., 82, 7889, 10.1073/pnas.82.23.7889 Ettinger, 1999, Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators, JAMA, 282, 637, 10.1001/jama.282.7.637 Sambrook, 2004, Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International, J. Intern. Med., 255, 503, 10.1111/j.1365-2796.2004.01317.x Goldstein, 2002, Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study, Am. J. Obstet. Gynecol., 187, 521, 10.1067/mob.2002.123938 Hendrix, 2001, Effect of selective estrogen receptor modulators on reproductive tissues other than endometrium, Ann. NY Acad. Sci., 949, 243, 10.1111/j.1749-6632.2001.tb04028.x Newberry, 1997, Fibroblast growth factor receptor signaling activates the human interstitial collagenase promoter via the bipartite Ets-AP1 element, Mol. Endocrinol., 11, 1129, 10.1210/me.11.8.1129 Frantz, 1994, Calcineurin acts in synergy with PMA to inactivate I kappa B/MAD3, an inhibitor of NF-kappa B, EMBO J., 13, 861, 10.1002/j.1460-2075.1994.tb06329.x Ernst, 1991, Functional estrogen receptors in osteoblastic cells demonstrated by transfection with a reporter gene containing an estrogen response element, Mol. Endocrinol., 5, 1597, 10.1210/mend-5-11-1597 Tzukerman, 1994, Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions, Mol. Endocrinol., 8, 21, 10.1210/me.8.1.21 Higuchi, 1988, A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interactions, Nucleic Acids Res., 16, 7351, 10.1093/nar/16.15.7351 Diascro, 1998, High fatty acid content in rabbit serum is responsible for the differentiation of osteoblasts into adipocyte-like cells, J. Bone Miner. Res., 13, 96, 10.1359/jbmr.1998.13.1.96 Kim, 2004, Estrogen receptor ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptor alpha modulators, J. Med. Chem., 47, 2171, 10.1021/jm034243o Lipfert, 2006, Antagonist-induced, AF-2 independent estrogen receptor {alpha} phosphorylation, Mol. Endocrinol., 20, 516, 10.1210/me.2005-0190 Nantermet, 2004, Androgenic induction of growth and differentiation in the rodent uterus involves the modulation of estrogen-regulated genetic pathways, Endocrinology, 146, 564, 10.1210/en.2004-1132 Yamamoto, 1998, The integrin ligand echistatin prevents bone loss in ovariectomized mice and rats, Endocrinology, 139, 1411, 10.1210/en.139.3.1411 Yamamoto, 1993, The effects of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats, Calcif. Tissue Int., 53, 278, 10.1007/BF01320914 Kato, 1995, Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase, Science, 270, 1491, 10.1126/science.270.5241.1491 Acevedo, 2004, Selective recognition of distinct classes of coactivators by a ligand-inducible activation domain, Mol. Cell, 13, 725, 10.1016/S1097-2765(04)00121-2 McClung, 2006, Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene, Menopause, 13, 377, 10.1097/01.gme.0000188736.69617.4f McDonnell, 1995, Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens, Mol. Endocrinol., 9, 659, 10.1210/me.9.6.659 Kedar, 1994, Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial, Lancet, 343, 1318, 10.1016/S0140-6736(94)92466-X Lahti, 1993, Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen, Obstet. Gynecol., 81, 660 B.R. Macdonald, Clinical assessment of the risk-to-benefit profile of idoxifene, NIH Workshop on SERMS, 2000, p. 143 Gennari, 2005, Lasofoxifene (Pfizer), Curr. Opin. Investig. Drugs, 6, 1067 Gruber, 2004, Bazedoxifene, Curr. Opin. Investig. Drugs, 5, 1086 Ronkin, 2005, Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women, Obstet. Gynecol., 105, 1397, 10.1097/01.AOG.0000163253.27610.b9